DPP4 and diabetic kidney disease: In a recently published narrative review of the evidence-based therapies of DKD, DPP-4 inhibitors have been addressed as one of the four effective therapeutic approaches.136 In accordance with this, one study suggested DPP-4 inhibitors as one of the albuminuria-l owering agents, which can be effectively used by crossover rotation to overcome resistance to renin–angiotensin–aldosterone system (RAAS) inhibitors.137